Garutadustat (ISM5411, PHD inhibitor)
Insilico Medicine: company profile
Phase 2 registry
Since , the date of the source that reports this phase.
Summary
Garutadustat is an ISM5411, PHD inhibitor from Insilico Medicine. It is being developed for ulcerative colitis. ClinicalTrials.gov lists it at Phase 2 (recruiting) under NCT07265570, NCT06012578. The AI role named in the source is molecule design. Registry records: NCT07265570, Phase 2, recruiting, updated Oct 29, 2026; NCT06012578, Phase 1, completed, updated Nov 7, 2024. About the company: Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation. The latest dated source is from Jul 1, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Insilico Medicine
- Indication
- Ulcerative colitis
- Therapeutic area
- Immunology and inflammation
- AI role
- Molecule design
- Phase in the source
- Phase 2, as of Jul 1, 2026
- Phase source
- Registry
- Board column
- Phase 2
AI evidence
AI source: Paper
“Our generative AI-powered Chemistry42 drug design platform produced this gut-restricted and safe PHD-specific inhibitor”
Source: paper (opens in new tab)
Trial records
- NCT07265570 on ClinicalTrials.gov (opens in new tab) Phase 2 Recruiting Updated
- NCT06012578 on ClinicalTrials.gov (opens in new tab) Phase 1 Completed Updated
Milestone timeline
-
NCT06012578 record updated
Phase 1, Completed
-
ClinicalTrials.gov record: Phase 2
-
NCT07265570 record updated
Phase 2, Recruiting
About Insilico Medicine
Pharma.AI, an end-to-end generative AI platform covering target discovery (PandaOmics), molecule generation (Chemistry42) and clinical prediction, backed by lab automation.
Spot an error? Tell me and I'll fix it.